Researchers from Moffitt Cancer Center have identified a new form of therapy for mantle cell lymphoma, which gives hope for more effective treatment. The inhibition of single transducer and activator of transcription 3 (STAT3) in mouse models of the disease causes the immune system to eradicate residual malignant cells responsible for disease relapse.
Dr. Eduardo M Sotomayor, lead author in the study, said “Despite good initial response to first-line treatment with chemotherapy and monoclonal antibodies, almost all patients with MCL will eventually relapse,” adding that “MCL has one of the worst prognoses among all B-cell non-Hodgkin lymphomas. Therefore, STAT3 inhibition is an effective strategy in mouse models of MCL and provides a framework for future use of STAT3 inhibitors in combination with drugs that are capable of repairing defective immune responses in lymphoma patients."
Moffitt researchers and colleagues have exploited evidence that suggests the manipulation of the patient’s own immune system might prove a good therapeutic strategy for patients with therapy-resistant MCL.
This study appears in the latest issue of Cancer Research published by the American Association for Cancer Research.